Applied Therapeutics' (APLT) "Sell (E+)" Rating Reiterated at Weiss Ratings

Key Points

• The stock of Applied Therapeutics (APLT) received a "sell (E+)" rating from Weiss Ratings and has a consensus target price of $4.13, despite mixed ratings from analysts.
• Recently, Applied Therapeutics' stock price fell to $1.08, with a significant drop in share trading volume compared to its average.
• The company reported earnings per share of ($0.15) for the last quarter, surpassing expectations, while analysts project a total of (0.65) EPS for the current fiscal year.

Applied Therapeutics (NASDAQ:APLT - Get Free Report)'s stock had its "sell (e+)" rating reiterated by research analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Applied Therapeutics to a "sell" rating in a research note on Saturday, July 26th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $4.13.

Applied Therapeutics Price Performance

APLT stock traded down $0.07 during midday trading on Tuesday, reaching $1.08. 1,533,166 shares of the stock were exchanged, compared to its average volume of 3,459,768. The stock has a market capitalization of $154.81 million, a PE ratio of -2.39 and a beta of 2.07. The company has a fifty day moving average price of $0.59 and a 200 day moving average price of $0.46. Applied Therapeutics has a 52 week low of $0.30 and a 52 week high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02. As a group, analysts anticipate that Applied Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Applied Therapeutics

A number of institutional investors have recently modified their holdings of the company. Propel Bio Management LLC boosted its stake in shares of Applied Therapeutics by 17.4% in the 1st quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company's stock valued at $5,517,000 after purchasing an additional 1,670,000 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Applied Therapeutics by 91.5% during the first quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company's stock valued at $5,076,000 after acquiring an additional 4,959,670 shares during the last quarter. Alyeska Investment Group L.P. boosted its position in Applied Therapeutics by 14.8% during the first quarter. Alyeska Investment Group L.P. now owns 3,107,497 shares of the company's stock valued at $1,519,000 after acquiring an additional 400,000 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Applied Therapeutics by 18.1% during the 2nd quarter. Marshall Wace LLP now owns 1,544,191 shares of the company's stock valued at $479,000 after purchasing an additional 236,810 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Applied Therapeutics during the 1st quarter valued at about $280,000. 98.31% of the stock is owned by institutional investors.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.